ENvue Medical Financials
This page shows ENvue Medical (FEED) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows balance-sheet expansion without commercial scaling, as goodwill swelled while gross profit on $2.6M of sales nearly vanished.
Total assets reached$41.1M in FY2025, yet the current ratio slipped to 1.1x because the balance sheet expanded mainly through goodwill rather than liquid working capital. So the company looked much larger on paper while cash was only$4.2M and free cash flow was-$9.4M , leaving operating liquidity far tighter than the asset total suggests and making the headline asset growth a poor guide to funding capacity.
With revenue roughly unchanged from FY2024, gross margin fell from
The FY2025 net loss of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of ENvue Medical's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ENvue Medical has an operating margin of -896.6%, meaning the company retains $-897 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -140.0% the prior year.
ENvue Medical's revenue declined 0.2% year-over-year, from $2.6M to $2.6M. This contraction results in a growth score of 43/100.
ENvue Medical carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
ENvue Medical's current ratio of 1.09 is below the typical benchmark, resulting in a score of 17/100. However, the company holds substantial cash reserves (63% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
While ENvue Medical generated -$9.4M in operating cash flow, capex of $60K consumed most of it, leaving -$9.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
ENvue Medical generates a -54.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -590.9% the prior year.
ENvue Medical passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, ENvue Medical generates $0.52 in operating cash flow (-$9.4M OCF vs -$18.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
ENvue Medical generated $2.6M in revenue in fiscal year 2025. This represents a decrease of 0.2% from the prior year.
ENvue Medical's EBITDA was -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 514.1% from the prior year.
ENvue Medical reported -$18.2M in net income in fiscal year 2025. This represents a decrease of 390.8% from the prior year.
ENvue Medical earned $-26.69 per diluted share (EPS) in fiscal year 2025. This represents an increase of 80.6% from the prior year.
Cash & Balance Sheet
ENvue Medical generated -$9.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 274.4% from the prior year.
ENvue Medical held $4.2M in cash against $0 in long-term debt as of fiscal year 2025.
ENvue Medical had 1M shares outstanding in fiscal year 2025. This represents an increase of 2803.9% from the prior year.
Margins & Returns
ENvue Medical's gross margin was 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 53.0 percentage points from the prior year.
ENvue Medical's operating margin was -896.6% in fiscal year 2025, reflecting core business profitability. This is down 756.5 percentage points from the prior year.
ENvue Medical's net profit margin was -712.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 567.5 percentage points from the prior year.
ENvue Medical's ROE was -54.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 536.6 percentage points from the prior year.
Capital Allocation
ENvue Medical invested $1.8M in research and development in fiscal year 2025. This represents an increase of 93.8% from the prior year.
ENvue Medical invested $60K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1900.0% from the prior year.
FEED Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $312K-56.8% | $722K+46.2% | $494K-51.8% | $1.0M+130.9% | $444K+18.1% | $376K-54.0% | $817K-11.3% | $921K |
| Cost of Revenue | $682K+28.0% | $533K+0.8% | $529K-19.4% | $656K+307.5% | $161K-33.7% | $243K-37.5% | $389K+51.4% | $257K |
| Gross Profit | -$370K-295.8% | $189K+640.0% | -$35K-109.5% | $369K+30.4% | $283K+112.8% | $133K-68.9% | $428K-35.5% | $664K |
| R&D Expenses | $39K-82.4% | $221K-77.3% | $972K+83.4% | $530K+50.6% | $352K+41.4% | $249K+33.2% | $187K+54.5% | $121K |
| SG&A Expenses | $2.6M+87.9% | $1.4M-37.7% | $2.3M+67.8% | $1.3M+19.2% | $1.1M+67.3% | $673K-6.0% | $716K-24.3% | $946K |
| Operating Income | -$14.8M-559.3% | -$2.2M+43.5% | -$4.0M-114.7% | -$1.9M-35.2% | -$1.4M-41.2% | -$970K-43.9% | -$674K-18.7% | -$568K |
| Interest Expense | N/A | $53K-63.2% | $144K+171.7% | $53K+55.9% | $34K+3.0% | $33K-2.9% | $34K0.0% | $34K |
| Income Tax | -$419K-1297.1% | $35K-43.5% | $62K+313.3% | $15K+200.0% | $5K+66.7% | $3K-25.0% | $4K-42.9% | $7K |
| Net Income | -$12.2M-2497.8% | $510K+112.8% | -$4.0M-59.2% | -$2.5M-74.4% | -$1.4M-43.4% | -$998K-45.1% | -$688K-17.0% | -$588K |
| EPS (Diluted) | N/A | $-0.91 | $-1.03 | $3.98 | N/A | $-3.56+86.9% | $-27.18-1242.0% | $2.38 |
FEED Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $41.1M-24.4% | $54.4M+5.6% | $51.5M+16.7% | $44.1M+1115.3% | $3.6M-22.5% | $4.7M-17.8% | $5.7M-8.6% | $6.2M |
| Current Assets | $7.3M-27.4% | $10.0M+45.3% | $6.9M+78.6% | $3.9M+15.9% | $3.3M-23.9% | $4.4M-18.7% | $5.4M-9.4% | $5.9M |
| Cash & Equivalents | $4.2M-39.2% | $7.0M+72.5% | $4.0M+570.5% | $601K-20.1% | $752K-42.4% | $1.3M-39.9% | $2.2M-19.6% | $2.7M |
| Inventory | $2.3M+4.2% | $2.2M+1.7% | $2.2M+9.3% | $2.0M-7.9% | $2.2M-2.6% | $2.3M-7.4% | $2.4M-6.1% | $2.6M |
| Accounts Receivable | $289K+14.7% | $252K+119.1% | $115K-67.9% | $358K+265.3% | $98K-83.1% | $580K+18.6% | $489K+35.8% | $360K |
| Goodwill | $29.1M-24.7% | $38.6M0.0% | $38.6M+13.9% | $33.9M | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.6M-36.0% | $11.9M+8.3% | $11.0M+30.5% | $8.4M+180.8% | $3.0M+6.8% | $2.8M-1.6% | $2.9M+4.5% | $2.7M |
| Current Liabilities | $6.7M-42.8% | $11.6M+78.0% | $6.5M-20.2% | $8.2M+201.2% | $2.7M+8.0% | $2.5M-1.4% | $2.6M+5.3% | $2.4M |
| Long-Term Debt | N/A | N/A | N/A | $1.3M | N/A | N/A | N/A | N/A |
| Total Equity | $33.5M-21.1% | $42.5M+4.9% | $40.5M+13.5% | $35.7M+5589.8% | $627K-66.5% | $1.9M-34.1% | $2.8M-18.9% | $3.5M |
| Retained Earnings | -$90.5M-17.7% | -$76.9M-1.1% | -$76.0M-5.1% | -$72.3M-3.6% | -$69.8M-2.1% | -$68.4M-1.5% | -$67.4M-1.0% | -$66.7M |
FEED Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M-35.8% | -$2.0M+41.8% | -$3.4M-151.9% | -$1.3M-145.1% | -$548K+34.4% | -$836K-51.2% | -$553K+4.5% | -$579K |
| Capital Expenditures | $23K-17.9% | $28K+600.0% | $4K-20.0% | $5K | $0 | $0-100.0% | $2K+100.0% | $1K |
| Free Cash Flow | -$2.7M-35.1% | -$2.0M+41.0% | -$3.4M-151.3% | -$1.3M-146.0% | -$548K+34.4% | -$836K-50.6% | -$555K+4.3% | -$580K |
| Investing Cash Flow | -$23K+17.9% | -$28K-600.0% | -$4K-102.8% | $143K | $0 | $0+100.0% | -$2K-100.0% | -$1K |
| Financing Cash Flow | -$34K-100.7% | $4.9M-28.2% | $6.8M+552.4% | $1.1M | $0+100.0% | -$27K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
FEED Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -118.6%-144.8pp | 26.2%+33.3pp | -7.1%-43.1pp | 36.0%-27.7pp | 63.7%+28.4pp | 35.4%-17.0pp | 52.4%-19.7pp | 72.1% |
| Operating Margin | -4748.1%-4436.9pp | -311.2%+493.6pp | -804.9%-624.2pp | -180.7%+127.9pp | -308.6%-50.6pp | -258.0%-175.5pp | -82.5%-20.8pp | -61.7% |
| Net Margin | -3919.6%-3990.2pp | 70.6%+874.5pp | -803.9%-560.4pp | -243.4%+78.9pp | -322.3%-56.9pp | -265.4%-181.2pp | -84.2%-20.4pp | -63.8% |
| Return on Equity | -36.5%-37.7pp | 1.2%+11.0pp | -9.8%-2.8pp | -7.0%+221.2pp | -228.2%-174.9pp | -53.3%-29.1pp | -24.2%-7.4pp | -16.8% |
| Return on Assets | -29.7%-30.7pp | 0.9%+8.7pp | -7.7%-2.1pp | -5.7%+33.8pp | -39.4%-18.1pp | -21.3%-9.2pp | -12.1%-2.7pp | -9.4% |
| Current Ratio | 1.09+0.2 | 0.86-0.2 | 1.05+0.6 | 0.47-0.8 | 1.22-0.5 | 1.74-0.4 | 2.11-0.3 | 2.45 |
| Debt-to-Equity | 0.23-0.1 | 0.280.0 | 0.27+0.2 | 0.04-4.8 | 4.79+3.3 | 1.50+0.5 | 1.00+0.2 | 0.78 |
| FCF Margin | -865.1%-588.3pp | -276.7%+408.9pp | -685.6%-554.1pp | -131.5%-8.1pp | -123.4%+98.9pp | -222.3%-154.4pp | -67.9%-4.9pp | -63.0% |
Frequently Asked Questions
What is ENvue Medical's annual revenue?
ENvue Medical (FEED) reported $2.6M in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ENvue Medical's revenue growing?
ENvue Medical (FEED) revenue declined by 0.2% year-over-year, from $2.6M to $2.6M in fiscal year 2025.
Is ENvue Medical profitable?
No, ENvue Medical (FEED) reported a net income of -$18.2M in fiscal year 2025, with a net profit margin of -712.3%.
What is ENvue Medical's EBITDA?
ENvue Medical (FEED) had EBITDA of -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ENvue Medical's gross margin?
ENvue Medical (FEED) had a gross margin of 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ENvue Medical's operating margin?
ENvue Medical (FEED) had an operating margin of -896.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is ENvue Medical's net profit margin?
ENvue Medical (FEED) had a net profit margin of -712.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is ENvue Medical's return on equity (ROE)?
ENvue Medical (FEED) has a return on equity of -54.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ENvue Medical's free cash flow?
ENvue Medical (FEED) generated -$9.4M in free cash flow during fiscal year 2025. This represents a -274.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ENvue Medical's operating cash flow?
ENvue Medical (FEED) generated -$9.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are ENvue Medical's total assets?
ENvue Medical (FEED) had $41.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ENvue Medical's capital expenditures?
ENvue Medical (FEED) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ENvue Medical spend on research and development?
ENvue Medical (FEED) invested $1.8M in research and development during fiscal year 2025.
What is ENvue Medical's current ratio?
ENvue Medical (FEED) had a current ratio of 1.09 as of fiscal year 2025, which is considered adequate.
What is ENvue Medical's debt-to-equity ratio?
ENvue Medical (FEED) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ENvue Medical's return on assets (ROA)?
ENvue Medical (FEED) had a return on assets of -44.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ENvue Medical's cash runway?
Based on fiscal year 2025 data, ENvue Medical (FEED) had $4.2M in cash against an annual operating cash burn of $9.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is ENvue Medical's Piotroski F-Score?
ENvue Medical (FEED) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ENvue Medical's earnings high quality?
ENvue Medical (FEED) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is ENvue Medical?
ENvue Medical (FEED) scores 26 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.